Obeticholic acid for the treatment of primary biliary cirrhosis

Expert Opinion on Orphan Drugs

Volumn 2, Issue 12, 2014, Pages 1351-1358

  Yimam, Kidist K ^a   Bowlus, Christopher L ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bile acid; Chenodeoxycholic acid; Farnesoid X receptor; Nuclear receptors; Obeticholic acid; Primary biliary cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; BILIRUBIN; BUDESONIDE; FARNESOID X RECEPTOR; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; OBETICHOLIC ACID; URSODEOXYCHOLIC ACID;

ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LIVER HISTOLOGY; MONOTHERAPY; PRIMARY BILIARY CIRRHOSIS; PRURITUS; SINGLE DRUG DOSE; VEIN THROMBOSIS;

EID: 84912101136     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.964206     Document Type: Article

References (39)

1. Momah N, Lindor KD. Primary biliary cirrhosis in adults. Expert Rev Gastroenterol Hepatol 2014;8:427-33
2. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009;50:291-308
3. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303
4. Kim WR, Lindor KD, Locke GR, et al. Epidemiology and natural history of primary biliary cirrhosis in a U.S. community. Gastroenterology 2000;119:1631-6
5. Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136:1281-7
6. Pares A, Caballeria L, Rodes J. Excellent long-Term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006;130:715-20
7. Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 2003;1:89-95
8. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-Term prognosis in primary biliary cirrhosis. Hepatology 2008;48:871-7
9. Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-Term outcome. J Hepatol 2011;55:1361-7
10. Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-Term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010;105:2186-94
11. Azemoto N, Kumagi T, Abe M, et al. Biochemical response to ursodeoxycholic acid predicts long-Term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res 2011;41:310-17
12. Zhang LN, Shi TY, Shi XH, et al. Early biochemical response to ursodeoxycholic acid and long-Term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 2013;58:264-72
13. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013;144:560-9
14. Czul F, Peyton A, Levy C. Primary biliary cirrhosis: therapeutic advances. Clin Liver Dis 2013;17:229-42
15. Lindor KD. Farnesoid X receptor agonists for primary biliary cirrhosis. Curr Opin Gastroenterol 2011;27:285-8
16. Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45:3569-72
17. Flores A, Mayo MJ. Primary biliary cirrhosis in 2014. Curr Opin Gastroenterol 2014;30:245-52
18. Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004;127:1497-512
19. Fiorucci S, Rizzo G, Antonelli E, et al. Cross-Talk between farnesoid-X-receptor (FXR) and peroxisome proliferatoractivated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005;315:58-68
20. Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014;59:2286-98
21. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012;17:988-97
22. Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999;117:918-25
23. Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005;41:747-52
24. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;31:318-23
25. Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- And late-stage primary biliary cirrhosis. Hepatology 2003;38:196-202
26. Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013;57:1931-41
27. Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008;38:557-64
28. Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011;33:235-42
29. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-8
30. Zhao C, Cong YL, Xu YJ, et al. Farnesoid X receptor in the study of fibrosis and its treatments. Chin Med J (Engl) 2013;126:3775-81
31. Fiorucci S, Mencarelli A, Palladino G, et al. Bile-Acid-Activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009;30:570-80
32. Elfaki DA, Bjornsson E, Lindor KD. Review article: nuclear receptors and liver disease - current understanding and new therapeutic implications. Aliment Pharmacol Ther 2009;30:816-25
33. Halilbasic E, Baghdasaryan A, Trauner M. Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis 2013;17:161-89
34. Mason A, Luketic V, Lindor K, et al. Farnesoid-X Receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (INT-747) to ursodeoxycholic acid. Hepatology 2010;52:375A
35. Hirschfield GM, Mason AL, Gordon SC, et al. A long term safety extension trial of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) and UDCA in primary biliary cirrhosis (PBC). Hepatology 2011;54:429A
36. Kowdley KV, Jones D, Luketic V; The OCA PBC Study Group. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol 2012;54:S13
37. Nevens F, Andreone P, Mazzella G, et al. The first primary biliary cirrhosis (PBC) phase 3 trial in two decades-An international study of the FXR agonist obeticholic acid in PBC patients.: journal of Hepatology. 2014;60:S525
38. Adorin L, Pencek R, Marmon T, et al. Long-Term treatment of primary biliary cirrhosis with the FXR agonist obeticholic acid shows durable efficacy. Programme and abstracts EASL monoconference on PBC; 23 - 24May 2014; Milan, Italy. P14
39. Intercept announces that FDA grants fast track designation to obeticholic acid for the treatment of patients with primary biliary cirrhosis. 2014. Available from: http://ir. interceptpharma.com/releasedetail.cfm? ReleaseID=851012 [Cited 7 September 2014